|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.66 CNY | +2.53% |
|
-3.50% | -6.48% |
| 03-03 | Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials | MT |
| 01-22 | Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95% | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 2 | |||||||
| 27 | |||||||
| 20 | |||||||
| 25 | |||||||
| 16 | |||||||
| 30 | |||||||
| 20 | |||||||
| 22 | |||||||
| 26 | |||||||
| 10 | |||||||
| 4 | |||||||
| 21 | |||||||
| 23 | |||||||
| 21 | |||||||
| 9 | |||||||
| - | 1 | ||||||
| 12 | |||||||
| 11 | |||||||
| - | - | ||||||
| Average | 17 | |||||||
| Weighted average by Cap. | 21 |
- Stock Market
- Equities
- 603087 Stock
- Sector Gan & Lee Pharmaceuticals.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition